Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinzaparin Biomarker Study in FIGO III-IV Ovarian Cancer Receiving Neoadjuvant Chemotherapy
2024-515450-24-00Phase 2Authorised
- Sponsor
- Region Östergötland
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of tinzaparin in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Region Östergötland. Planned start Oct 2024; status: authorised.
02
Drugs
tinzaparin
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2024-515450-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515450-24-00.